新型阿片类药物奥赛利定

The new opioid drug oliceridine

阿片类药物是治疗中至重度疼痛的基石,但其临床应用受到了阿片类药物相关不良反应(opioid‑related adverse event,ORAE)的限制。新型G蛋白偏向性µ阿片受体激动剂奥赛利定由于其独特的药理特性可减少ORAE的发生率。文章综述奥赛利定的药理学特性及其治疗中至重度急性疼痛有效性和安全性的临床研究,着重阐述奥赛利定减少阿片类药物诱导的呼吸抑制(opioid‑induced respiratory depression,OIRD)、胃肠道不良反应等安全性的临床研究,并探讨其在围手术期镇痛、无痛内镜和烧伤、慢性疼痛等非围手术期疼痛管理的临床应用价值,以期为临床疼痛管理提供一种新选择。

Opioids are the cornerstone in the treatment of moderate to severe pain but their clinical application is limited by opioid‑related adverse events(ORAE).Oliceridine,a new G protein‑biasedµopioid receptor agonist can reduce the incidence of ORAE due to its unique pharmacological properties.This review summarizes the pharmacological properties of oliceridine and the clini‑cal studies on its efficacy and safety in the treatment of moderate to severe acute pain,focusing on the clinical studies on the safety of oliceridine in reducing opioid‑induced respiratory depression(OIRD)and gastrointestinal adverse reactions,and introduces its clinical application value in postoperative analgesia,painless endoscopy and non‑perioperative pain management such as burn and chronic pain,that it is expected to provide a new option for clinical pain management.